• 09 May 2013 Junaxo Inc incorporated in Toronto

  • 26 September 2013 Junaxo Inc. in-licences Phase II ready clinical programme JNX1001

  • 08 December 2013 Junaxo presents at ALS conference in Milan  

  • 16 october 2013 Junaxo Inc. receives $1M MJFF grant to support JNX3001 project [more]

  • 05 May 2014 Junaxo presents ALS program at ALS-Canada meeting in Toronto

  • Junaxo in-licences Phase II ready program for treatment of dyskinesia in Parkinson’s disease – JNX4022 - July 2015​
    Junaxo presents at 5th Annual Biotechnology and human health symposium, July 2014, Charlottetown, PEI, Canada​ [MORE]

.

NEWS ARCHIVE